Anti-Mouse CD120b (TNFR2) [Clone TR75-54.7] — Purified in vivo GOLD™ Functional Grade

Clone TR75-54.7 is widely used in vivo in mice for studies targeting mouse TNFR2 (CD120b), primarily to investigate antitumor immunity, tumor growth suppression, and immune modulation.

Key in vivo applications include:

• Enhancing anti-tumor immunity and promoting immune responses against tumors, particularly in immunocompetent mouse models.
• Inhibition of tumor growth in preclinical cancer models, notably the 4T1 breast cancer model, where TR75-54.7 administration results in significant tumor regression and increased overall survival of treated mice.
• Blockade of ligand-induced TNFR2 signaling, which modulates processes such as immunoregulation, cell proliferation, apoptosis, and inflammation.
• Combination immunotherapy studies: TR75-54.7 is frequently used alongside other agents, such as anti-CD25 (PC61) or checkpoint inhibitors like anti-PD-L1, to evaluate synergistic or additive effects on tumor rejection and survival.
• Generation of tumor-specific immunity: TR75-54.7 treatment has resulted in long-term protection against subsequent challenge with the same tumor cells, indicating robust tumor-specific memory responses.
• As a functional blocking antibody, TR75-54.7 is applied for mechanistic studies of TNFR2 signaling in vivo, helping to clarify its role in regulatory T cell function, hematopoiesis, and inflammatory disease models.

Additional in vivo uses:

• Flow cytometry to track TNFR2+ cells and immune subsets following antibody administration.
• ELISA capture antibody for quantifying TNFR2 or monitoring treatment effects.

These applications make TR75-54.7 an essential tool in immuno-oncology and immunoregulation studies in mice, especially for dissecting TNFR2's role in tumor immunity and therapeutic antibody development.

Commonly used antibodies or proteins in conjunction with TR75-54.7 (an anti-TNFR2/CD120b antibody) include:

• TR75-32.4: This antibody targets the same molecule (TNFR2) and is frequently paired with TR75-54.7 in assays such as ELISA, where TR75-54.7 serves as the capture antibody and TR75-32.4 (often biotinylated) as the detection antibody.
• PC61: An anti-CD25 (IL-2Rα) monoclonal antibody widely used in immunology research, notably for regulatory T cell (Treg) depletion experiments in tumor immunology. Studies often combine TR75-54.7 with PC61 to investigate synergistic effects on Treg cell targeting and antitumor immunity.
• Anti-PD-L1 (B7H1) antibody (Clone 10F.9G2): Used in combination with TR75-54.7 in cancer immunotherapy research to study co-blockade of immune checkpoints.
• Secondary antibodies: Such as biotinylated anti-Armenian hamster IgG or streptavidin-PE (SAv-PE), are used for detection when primary antibodies like TR75-54.7 are unconjugated.
• Cytokines and Ligands: TNF-α and LT-α (ligands for TNFR2) may be added in vitro to stimulate or challenge cells prior to blockade with TR75-54.7.

Typical experiments in the literature using TR75-54.7 frequently employ the following combinations:

• TR75-54.7 (capture) + TR75-32.4 (detector) for ELISA.
• TR75-54.7 + PC61 for functional Treg studies and tumor models.
• TR75-54.7 + anti-PD-L1 (10F.9G2) for combinatory immunotherapy.

These pairings are often chosen based on the experimental goal (e.g., flow cytometry, ELISA, in vivo Treg depletion, or combined checkpoint blockade in tumor models).

Clone TR75-54.7 is a monoclonal antibody that targets mouse Tumor Necrosis Factor Receptor Type II (TNFR2), also known as CD120b or p75. Key findings from its citations in scientific literature are as follows:

Key Findings

1. TNFR2 Agonism vs. Antagonism: TR75-54.7 acts as a TNFR2 agonist when cross-linked in vitro, promoting cell proliferation and NF-κB activation. However, it is also characterized as a functional blocking antibody, suggesting it can block ligand-induced receptor signaling under certain conditions.

2. Antitumor Effects: The antibody has been shown to inhibit tumor growth more effectively than CD25 antagonistic antibodies in certain mouse models. It enhances survival in tumor-bearing mice and is particularly effective when combined with other therapies like CD25 blockade.

3. Mechanism and Relevance: TNFR2 is involved in various biological processes, including immunoregulation, apoptosis, and cell differentiation. The receptor's activation can lead to NF-κB signaling, which plays a role in inflammation and immune responses.

4. Therapeutic Potential: The combination of anti-TNFR2 antibodies with other immunotherapies, such as anti-PD-L1, has been explored for enhanced antitumor effects.

5. Experimental Use: TR75-54.7 is used in research for detecting mouse TNFR2 by flow cytometry and ELISA, acting as a capture antibody when paired with other antibodies.

Dosing regimens for clone TR75-54.7 (anti-mouse TNFR2) vary by mouse strain, tumor type, and experimental protocol, with specific details reported for FVB/n, C57BL/6j, NSG, Balb/c, CT26, and JAK2+/VF models.

• Strain and Tumor Model Variation:

  • Dosing is adapted for mouse strain (e.g., FVB/n, C57BL/6j, NSG, Balb/c) and the type and location of tumor engraftment.
  • For pancreatic cancer models, commonly used strains are FVB/n, C57BL/6j, and NSG, with protocols adjusted for tumor site and burden.
  • In a 4T1 breast cancer model using Balb/c mice, TR75-54.7 was given via intraperitoneal injection before tumor cell inoculation.
  • For colorectal cancer (CT26) in immunocompetent mice, TR75-54.7 was administered i.p. (intraperitoneally) at 100 μg per injection on days 11, 14, and 18 after tumor engraftment.

• Hematological Malignancy/Inflammation Model:

  • In a myeloproliferative neoplasm (JAK2+/VF mice), dosing was 5 mg/kg body weight twice a week for 3 weeks by i.p. injection.

• General Considerations:

  • Experimenters select mouse strain and adjust dose frequency, route (often i.p.), and concentration to optimize for tumor type, immunological context, and desired antitumor effect.
  • Reported regimens range from 100 μg/injection (for tumor inhibition studies) to 5 mg/kg twice weekly (for inflammatory disease models).
  • Dosing is typically started before or after tumor cell implantation depending on study goals (prevention vs. treatment).

• Combination Treatments:

  • TR75-54.7 is sometimes co-administered with antibodies targeting other immune regulators (e.g., anti-CD25 PC61) or checkpoint inhibitors, further influencing dosing schedules and outcomes.

Key regimen examples:

Regimens should always be tailored based on mouse strain, tumor type, disease context, and desired experimental outcome. Always consult published protocols for your specific model; adjust dose and schedule as needed for immunological or pharmacokinetic differences across strains.